TNFSF11 and triple-negative breast carcinoma: As additional controls and to account for any potential alterations in soluble factors that may be produced by GFP-MDA-MB-231 cells versus parental MDA-MB-231 cells, we also tri-cultured RAW 264.7 pre-osteoclasts in the presence of exogenous RANKL for six days with MDA-MB-231 GFP/luc2 human triple negative breast cancer cells (i) plus naïve osteoblasts (control) or (ii) plus EO-231 cells in-vitro (Figure S5).